<p>/PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM)（以下简称 “公司”）今天宣布，其董事会（以下简称 “董事会”）已批准，公司打算自纳斯达克证券市场（“纳斯达克”）自愿退市，并注销其普通股，以暂停并最终终止公司根据 1934 年证券交易法（修订版）（“交易法”）的报告义务。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg"/></p>
<p>如之前所述，由于公司之前披露的未能遵守纳斯达克上市规则 5450(a)(1)、5450(b)(2)(C) 和 5450(b)(2)(A) 中规定的最低报价、上市证券的市场价值和公众持有股份的市场价值要求，公司于 2025 年 10 月 9 日收到了纳斯达克的退市决定函（“决定函”），并且公司的普通股自 2025 年 10 月 13 日起暂停在纳斯达克交易。公司的普通股于 2025 年 10 月 13 日在 OTCID 市场层级开始交易，交易代码为 “CARM”。</p>
<p>决定函指出，一旦所有适用的上诉期限届满，纳斯达克将向证券交易委员会（“SEC”）提交一份 25 号表格，以完成公司普通股从纳斯达克的退市。尽管如此，公司今天通知纳斯达克，其打算自愿退市，而不是等待纳斯达克在稍后的日期提交 25 号表格。公司预计将在 2025 年 12 月 15 日左右向 SEC 提交 25 号表格，以实施普通股的退市和注销，并且公司的普通股从纳斯达克的正式退市预计将在 2025 年 12 月 25 日左右生效。</p>
<p>在公司普通股从纳斯达克退市后，公司打算向 SEC 提交 15 号表格，以暂停并最终终止其根据交易法的报告义务。公司将在注销生效后解除所有根据交易法的报告义务。公司预计其普通股的注销将在向 SEC 提交 15 号表格后 90 天生效。提交给 SEC 的文件将在公司网站上提供，网址为 https://carismatx.com/。</p>
<p>董事会在仔细考虑多个因素后决定加速普通股的退市和注销，包括收到纳斯达克的决定函、纳斯达克预计将按时提交 25 号表格，以及公司正在持续进行有序结束其运营的努力。</p>
<p><strong>关于 Carisma Therapeutics</strong></p>
<p>Carisma Therapeutics 是一家生物技术公司，之前专注于利用其在巨噬细胞工程方面的行业领先专业知识，开发变革性疗法以治疗包括肝纤维化和癌症在内的严重疾病。Carisma 总部位于宾夕法尼亚州费城。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法》所定义的前瞻性声明，包括但不限于关于从纳斯达克退市和公司普通股注销的预期时间、公司保持现金以充分资助公司运营有序结束的能力，以及公司为最大化其现金状况以惠及利益相关者所采取的行动的声明。&#34;预计&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期待&#34;、&#34;希望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;目标&#34;、&#34;应该&#34;、&#34;会&#34;及类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和预期大相径庭，包括在 Carisma 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 标题下描述的风险，该报告最初于 2025 年 3 月 31 日向 SEC 提交，并由 2025 年 4 月 29 日向 SEC 提交的年度报告修正案第 1 号修正，以及随后向 SEC 提交的季度报告，每份报告均已向 SEC 备案，以及公司未来可能向 SEC 提交的其他文件中描述的风险。除法律另有要求外，公司不承担更新或修订任何前瞻性声明以反映该声明日期后事件或情况的义务。</p>
<p><strong>联系方式</strong>：</p>
<p>Steven Kelly</p>
<p>steven.kelly@carismatx.com</p>
<p>来源：Carisma Therapeutics Inc.</p>

CARM

<p>Carisma Therapeutics Inc. 宣布自愿从纳斯达克退市，并向美国证券交易委员会（SEC）申请注销，以终止其报告义务。此决定是由于未遵守纳斯达克上市规则而作出的退市决定。该公司的股票将转在 OTCID 市场交易。退市预计将在 2025 年 12 月 25 日生效，注销将在提交 Form 15 后 90 天生效。Carisma 旨在保留现金，以便有序结束运营</p>

<p>, /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the &#34;Company&#34;) today announced that its Board of Directors (the &#34;Board&#34;) has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) and the deregistration of its common stock in order to suspend and ultimately terminate the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM)（以下简称 “公司”）今天宣布，其董事会（以下简称 “董事会”）已批准，公司打算自纳斯达克证券市场（“纳斯达克”）自愿退市，并注销其普通股，以暂停并最终终止公司根据 1934 年证券交易法（修订版）（“交易法”）的报告义务。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/1219543/Carisma_Therapeutics_Logo.jpg"/></p>
<p>As previously reported, as a result of the Company's previously disclosed noncompliance with the bid price, market value of listed securities, and market value of publicly held shares requirements set forth in Nasdaq Listing Rules 5450(a)(1), 5450(b)(2)(C), and 5450(b)(2)(A), respectively, the Company received a delist determination letter from Nasdaq on October 9, 2025 (the &#34;Determination Letter&#34;) and the Company's common stock was suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Company's common stock commenced trading on the OTCID market tier operated by the OTC Markets Group on October 13, 2025, under the trading symbol &#34;CARM.&#34;</p>
<div class="lb-trans"><p>如之前所述，由于公司之前披露的未能遵守纳斯达克上市规则 5450(a)(1)、5450(b)(2)(C) 和 5450(b)(2)(A) 中规定的最低报价、上市证券的市场价值和公众持有股份的市场价值要求，公司于 2025 年 10 月 9 日收到了纳斯达克的退市决定函（“决定函”），并且公司的普通股自 2025 年 10 月 13 日起暂停在纳斯达克交易。公司的普通股于 2025 年 10 月 13 日在 OTCID 市场层级开始交易，交易代码为 “CARM”。</p>
</div><p>The Determination Letter indicated that, once all applicable appeal periods had lapsed, Nasdaq would file a Form 25 with the Securities and Exchange Commission (the &#34;SEC&#34;) to complete the delisting of the Company's common stock from Nasdaq. Notwithstanding, the Company today notified Nasdaq of its intention to voluntarily delist its shares of common stock from Nasdaq rather than await Nasdaq's filing of a Form 25 at some later date. The Company anticipates that it will file a Form 25 with the SEC to effect the delisting and deregistration of its common stock on or about December 15, 2025 and that the formal delisting of the Company's common stock from Nasdaq will become effective on or about December 25, 2025.</p>
<div class="lb-trans"><p>决定函指出，一旦所有适用的上诉期限届满，纳斯达克将向证券交易委员会（“SEC”）提交一份 25 号表格，以完成公司普通股从纳斯达克的退市。尽管如此，公司今天通知纳斯达克，其打算自愿退市，而不是等待纳斯达克在稍后的日期提交 25 号表格。公司预计将在 2025 年 12 月 15 日左右向 SEC 提交 25 号表格，以实施普通股的退市和注销，并且公司的普通股从纳斯达克的正式退市预计将在 2025 年 12 月 25 日左右生效。</p>
</div><p>Following the delisting of the Company's common stock from Nasdaq, the Company intends to file a Form 15 with the SEC to suspend and then terminate its reporting obligations under the Exchange Act. The Company will be relieved of all reporting obligations under the Exchange Act upon the effectiveness of the deregistration. The Company expects that the deregistration of its common stock will become effective 90 days after the filing of the Form 15 with the SEC. The documents filed with the SEC will be available on the Company's website at https://carismatx.com/.</p>
<div class="lb-trans"><p>在公司普通股从纳斯达克退市后，公司打算向 SEC 提交 15 号表格，以暂停并最终终止其根据交易法的报告义务。公司将在注销生效后解除所有根据交易法的报告义务。公司预计其普通股的注销将在向 SEC 提交 15 号表格后 90 天生效。提交给 SEC 的文件将在公司网站上提供，网址为 https://carismatx.com/。</p>
</div><p>The Board determined to accelerate the delisting and deregistration of its common stock after careful consideration of numerous factors, including receipt of the Determination Letter from Nasdaq, the expected filing in due course of a Form 25 by Nasdaq, and the Company's ongoing pursuit of an orderly wind down of its operations.</p>
<div class="lb-trans"><p>董事会在仔细考虑多个因素后决定加速普通股的退市和注销，包括收到纳斯达克的决定函、纳斯达克预计将按时提交 25 号表格，以及公司正在持续进行有序结束其运营的努力。</p>
</div><p><strong>About Carisma Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Carisma Therapeutics</strong></p>
</div><p>Carisma Therapeutics is a biotechnology company that was previously focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. Carisma is headquartered in Philadelphia, PA.</p>
<div class="lb-trans"><p>Carisma Therapeutics 是一家生物技术公司，之前专注于利用其在巨噬细胞工程方面的行业领先专业知识，开发变革性疗法以治疗包括肝纤维化和癌症在内的严重疾病。Carisma 总部位于宾夕法尼亚州费城。</p>
</div><p><strong>Cautionary Note Regarding Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the expected timing of the delisting from Nasdaq and deregistration of the Company's common stock, the Company's ability to preserve cash in order to adequately fund an orderly wind down of the Company's operations, and the Company's actions to maximize the Company's cash position for the benefit of its stakeholders. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;hope,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;target,&#34; &#34;should,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including those risks described under the caption &#34;Risk Factors&#34; in Carisma's Annual Report on Form 10-K for the year ended December 31, 2024, which was originally filed with the SEC on March 31, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K/A, which was filed with the SEC on April 29, 2025 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, each of which is on file with the SEC, and risks described in other filings that the Company may make with the SEC in the future. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect events or circumstances after the date of such statements for any reason, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法》所定义的前瞻性声明，包括但不限于关于从纳斯达克退市和公司普通股注销的预期时间、公司保持现金以充分资助公司运营有序结束的能力，以及公司为最大化其现金状况以惠及利益相关者所采取的行动的声明。&#34;预计&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期待&#34;、&#34;希望&#34;、&#34;打算&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;目标&#34;、&#34;应该&#34;、&#34;会&#34;及类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。实际结果或事件可能因各种重要因素而与这些前瞻性声明中披露的计划、意图和预期大相径庭，包括在 Carisma 截至 2024 年 12 月 31 日的年度报告的 “风险因素” 标题下描述的风险，该报告最初于 2025 年 3 月 31 日向 SEC 提交，并由 2025 年 4 月 29 日向 SEC 提交的年度报告修正案第 1 号修正，以及随后向 SEC 提交的季度报告，每份报告均已向 SEC 备案，以及公司未来可能向 SEC 提交的其他文件中描述的风险。除法律另有要求外，公司不承担更新或修订任何前瞻性声明以反映该声明日期后事件或情况的义务。</p>
</div><p><strong>Contact</strong>:</p>
<div class="lb-trans"><p><strong>联系方式</strong>：</p>
</div><p>Steven Kelly</p>
<div class="lb-trans"><p>Steven Kelly</p>
</div><p>steven.kelly@carismatx.com</p>
<div class="lb-trans"><p>steven.kelly@carismatx.com</p>
</div><p>SOURCE Carisma Therapeutics Inc.</p>
<div class="lb-trans"><p>来源：Carisma Therapeutics Inc.</p>
</div>

Carisma 宣布从纳斯达克退市并注销美国证券交易委员会登记 | CARM 股票新闻